1. Introduction {#sec1}
===============

Breast cancer has been at the forefront of cancer research over the last 40 years. This has led to a 32% reduction of breast cancer mortality in the United Kingdom (UK) since the early 1970s \[[@bib1]\]. However, despite earlier detection and improvements in treatment, some women do not respond thereby resulting in metastatic disease and death. We hypothesized that there is a sub-group of women consistently present over the last several decades who have cancers that are inherently resistant to therapy. To test this hypothesis, the changes in outcomes and patterns of response to treatment in breast cancer patients treated over 40 years were assessed.

2. Material and methods {#sec2}
=======================

Between January 1975 and December 2006, a total of 6361 women were diagnosed with invasive breast cancer at Guy's Hospital in London. Data, including patient demographics, tumour characteristics, treatment modality, and follow-up data on local recurrence, pattern of metastasis and death, were prospectively recorded. Patients were excluded from analysis if their initial surgery took place more than six months after initial diagnosis, based on the assumption that a delayed surgery of more than six months would not have corresponded to routine treatment standards and was most likely for reasons outside normal clinical care. Women receiving neo-adjuvant chemotherapy were included in this study.

2.1. Time period cohorts {#sec2.1}
------------------------

Women were divided into four different time periods based on year of surgery: 1975--1982, 1983--1990, 1991--1998, 1999--2006, denoted P1, P2, P3, and P4. The time periods were selected to divide the study subjects into four similarly sized cohorts. They also coincided with periods of change in breast cancer care in the UK, such as the introduction of tamoxifen (1972), 5-fluorouracil chemotherapy (1976), anthracyclines (1980s), taxanes (1990s) and trastuzumab (Herceptin®) (2001) and the introduction of the National Health Service Breast Screening Programme (NHSBSP) (1988) \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6]\].

2.2. Statistical analyses {#sec2.2}
-------------------------

The four periods were compared based on patient outcome with regard to time to distant metastases, time from metastases to death, and overall survival, by means of Cox proportional hazards model summarised by hazard ratios (HR) and 95%-conﬁdence intervals (95%-CI). Kaplan-Meier estimation was used to graphically illustrate time to event analysis.

2.3. Follow-up {#sec2.3}
--------------

To ensure follow-up times in the different surgery year groups were comparable, the following dates for end of follow-up were applied: for P1 June 1991; for P2 June 1999; for P3 June 2007; and for P4 June 2015 making all analyses limited to a maximum follow-up of approximately 16 years.

2.4. Overall survival from primary disease {#sec2.4}
------------------------------------------

In a first analysis, the overall survival from date of surgery to date of death or end of follow-up, whichever came first, was compared. The model was adjusted for an increasing set of predetermined potentially confounding factors, including biological characteristics of the carcinoma (invasive tumour size, nodal status, histological grade, oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2)), and adjuvant/neoadjuvant treatments (chemotherapy, radiotherapy and endocrine treatment) in combination with surgery.

Methods of determining ER and PgR status varied over the study period. When enzyme immunoassay (EIA) was used, a positive result cut-off was defined as \>15 fmol/mg protein, for the dextran-coated charcoal (DCC) ligand binding assay the cut-off was \>20 fmol/mg and for immunochemistry (IHC) either a Quick score divided as 0--3 versus 4--7 or subsequently the Allred score 0--2 versus 3--8 were applied \[[@bib7], [@bib8], [@bib9], [@bib10]\]. For HER2 status, IHC was used as the first line test, according to UK HER2 testing guidelines, with scores of 0--1 (negative) versus score 3 (positive) \[[@bib10], [@bib11], [@bib12]\]. Equivocal results (score 2+) were further assessed using fluorescence in situ hybridisation (FISH) and a ratio of \>2.00 of HER2 gene to chromosome 17 centromeric probe was defined as HER2 amplified for this series \[[@bib10], [@bib11], [@bib12]\].

2.5. Overall survival from onset of metastasis {#sec2.5}
----------------------------------------------

The proportion of women developing secondary distant metastases ≤8 years from surgery was examined. *De novo* metastatic disease has not been included. The women with distant metastases were further subdivided into four categories, determined by the proportions of deaths occurring ≤1 year, from 1 to 2, 2--4, and 4 + years from the date of diagnosis of distant metastases.

2.6. Onset of metastasis {#sec2.6}
------------------------

In a further analysis, the four time periods were compared regarding time from surgery to time to development of secondary distant metastases; this was defined as the date of clinical diagnosis of metastasis or date of death in case of post-mortem metastatic disease diagnosis (P1: n = 37, P2: n = 34, P3: n = 40, P4: n = 24), the date of breast cancer-related death or last follow-up, whichever came first. The same set of models adjusting for potential confounders as above was used. Finally, a comparison was made between the four time periods for variation in time from diagnosis of distant metastases to death or end of follow-up, whichever came first. In addition to the potential confounders presented above, all treatments administered during the whole period, from first diagnosis to those treatments prescribed for metastatic disease, were included in this analysis.

2.7. Risk groups {#sec2.7}
----------------

To identify various risk groups in each time period, women were categorized based on the St. Gallen breast cancer risk criteria and the histological grade of the primary tumour, both independent of each other important verified prognostic features \[[@bib13]\]. The three resulting groups were defined as follows: low risk = St. Gallen low and intermediate risk categories; intermediate risk = St. Gallen high risk category (i.e. node positive (1--3 nodes) AND ER & PgR negative OR HER2 overexpressed/amplified OR just ≥4 lymph nodes involved) with grade 1 or 2 invasive breast cancer; high risk = St. Gallen high risk category, with grade 3 invasive breast cancer (detailed definition in [Table 1](#tbl1){ref-type="table"}).Table 1Definitions of risk categories as per St Gallen 2007 and as devised in this research for patients with operable breast cancer.Table 1*Risk category*St Gallen criteriaOur risk criteria*Low risk***Node negative** AND **Grade 1**[a](#tbl1fna){ref-type="table-fn"} AND\
pT[b](#tbl1fnb){ref-type="table-fn"} ≤2 cm, AND\
Absence of extensive peritumoral vascular invasion, AND\
ER and/or PgR[c](#tbl1fnc){ref-type="table-fn"} expressed, AND\
HER2/*neu* gene neither overexpressed nor amplified, AND\
Age ≥35 years**Node negative** AND** Grade 1**[a](#tbl1fna){ref-type="table-fn"} AND\
pT[b](#tbl1fnb){ref-type="table-fn"} ≤2 cm, AND\
With or without extensive peritumoral vascular invasion, AND\
ER and/or PgR[c](#tbl1fnc){ref-type="table-fn"} expressed, AND\
HER2/*neu* gene neither overexpressed nor amplified, AND\
Age ≥35 years\
OR\
**Node negative** AND\
Grade 2-3[a](#tbl1fna){ref-type="table-fn"}, OR\
pT[b](#tbl1fnb){ref-type="table-fn"} \>2 cm, OR\
Presence of extensive peritumoral vascular invasion, OR\
ER and PgR absent, OR\
HER2/*neu* gene overexpressed or amplified, OR\
Age \<35 years\
OR\
**Node positive (1-3 involved nodes)** AND\
ER and/or PgR expressed, AND\
HER2/*neu* gene neither overexpressed nor amplified*Intermediate risk***Node negative** AND\
Grade 2-3[a](#tbl1fna){ref-type="table-fn"}, OR\
pT[b](#tbl1fnb){ref-type="table-fn"} \>2 cm, OR\
Presence of extensive peritumoral vascular invasion, OR\
ER and PgR absent, OR\
HER2/*neu* gene overexpressed or amplified, OR\
Age \<35 years\
OR\
**Node positive (1-3 involved nodes)** AND\
ER and/or PgR expressed, AND\
HER2/*neu* gene neither overexpressed nor amplified**Node positive (1-3 involved nodes)** [AND]{.ul}**[Grade 1-2]{.ul}**[a](#tbl1fna){ref-type="table-fn"} AND\
ER and PgR absent, OR\
HER2/*neu* gene overexpressed or amplified\
OR\
**Node positive (4 or more involved nodes)**[AND]{.ul}**[Grade 1-2]{.ul}**[a](#tbl1fna){ref-type="table-fn"}*High risk***Node positive (1-3 involved nodes)** AND\
ER and PgR absent, OR\
HER2/*neu* gene overexpressed or amplified\
OR\
**Node positive (4 or more involved nodes)Node positive (1-3 involved nodes)**[AND]{.ul}**[Grade 3]{.ul}**[a](#tbl1fna){ref-type="table-fn"} AND\
ER and PgR absent, OR\
HER2/*neu* gene overexpressed or amplified\
OR\
**Node positive (4 or more involved nodes)**[AND]{.ul}**[Grade 3]{.ul}**[a](#tbl1fna){ref-type="table-fn"}[^1][^2][^3]

2.8. Missing data {#sec2.8}
-----------------

For missing data, multiple imputations by chained equations (MICE) were performed to complete the dataset. All statistical analyses were performed using the statistical program package R (<http://www.R-project.org>).

3. Results {#sec3}
==========

3.1. Surgery {#sec3.1}
------------

Of the total 6361 women diagnosed with invasive breast cancer, 5392 (84.8%) underwent surgery within 6 months of first diagnosis. For the 4 time periods the percentage receiving surgery within 6 months after diagnosis was 83.7%, 83.1%, 87.6%, and 84.8% respectively. The basic patient demographics, tumour characteristics, and treatment modalities for those women who underwent surgery can be seen in [Table 2](#tbl2){ref-type="table"}.Table 2Demographic features, histopathological characteristics and treatment modalities of women with invasive breast cancer who underwent surgery between 1975 and 2006, divided into four time periods.ER = oestrogen receptor, PgR = progesterone receptor, HER2 = human epithelial growth factor receptor 2.Table 21975--1982 (n = 1381)1983--1990 (n = 1333)1990--1998 (n = 1382)1999--2006 (n = 1296)Age at diagnosis, n (%)\<40105(7.6)124(9.3)112(8.1)130(10.0)40--49362(26.2)254(19.1)296(21.4)242(18.7)50--59406(29.4)371(27.8)393(28.4)354(27.3)60--69305(22.1)350(26.3)309(22.4)294(22.7)70+203(14.7)234(17.6)272(19.7)276(21.3)**Nodal status, n (%)**Negative621(45.0)576(43.2)603(43.6)549(42.4)Positive601(43.5)580(43.5)632(45.7)500(38.6)Missing159(11.5)177(13.3)147(10.6)247(19.1)**Nodal number, n (%)**0621(45.0)576(43.2)603(43.6)549(42.4)1--3352(25.5)354(26.6)403(29.2)335(25.8)4+249(18.0)226(17.0)229(16.6)165(12.7)Missing159(11.5)177(13.3)147(10.6)247(19.1)**Tumour size, n (%)**\<2 cm402(29.1)479(35.9)757(54.8)614(47.4)2--5 cm892(64.6)780(58.5)556(40.2)580(44.8)5 + cm56(4.1)52(3.9)53(3.8)68(5.2)Missing31(2.2)22(1.7)16(1.2)34(2.6)**Histological type, n (%)**Ductal1113(80.6)1088(81.6)1115(80.7)964(74.4)Lobular122(8.8)154(11.6)166(12.0)105(8.1)Other/missing146(10.6)91(6.8)101(7.3)227(17.5)**Grade, n (%)**Grade 1131(9.5)141(10.6)233(16.9)178(13.7)Grade 2620(44.9)543(40.7)400(28.9)456(35.2)Grade 3371(26.9)418(31.4)520(37.6)434(33.5)Unknown/missing259(18.8)231(17.3)229(16.6)228(17.6)**ER-status, n (%)**Negative437(31.6)346(26.0)298(21.6)231(17.8)Positive786(56.9)899(67.4)978(70.8)904(69.8)Missing158(11.4)88(6.6)106(7.7)161(12.4)**PgR-status, n (%)**Negative627(45.4)600(45.0)500(36.2)384(29.6)Positive534(38.7)638(47.9)776(56.2)752(58.0)Missing220(15.9)95(7.1)106(7.7)160(12.3)**HER2-status, n (%)**Negative404(29.3)573(43.0)660(47.8)689(53.2)Positive110(8.0)157(11.8)177(12.8)197(15.2)Missing867(62.8)603(45.2)544(39.4)410(31.6)**High risk subpopulation**[a](#tbl2fna){ref-type="table-fn"}St Gallen 'High Risk' + Grade 3\
Other/missing177\
1204(12.8)\
(87.2)183\
1150(13.7)\
(86.3)222\
1160(16.1)\
(83.9)196\
1100(15.1)\
(84.9)**Surgery, n (%)**Mastectomy1177(85.2)671(50.3)546(39.5)513(39.6)Breast conservation204(14.8)662(49.7)836(60.5)783(60.4)**(Neo)adjuvant Radiation therapy, n (%)**Yes250(18.1)550(41.3)817(59.1)877(67.7)No1131(81.9)783(58.7)565(40.9)419(32.3)**Adjuvant endocrine therapy, n (%)**No endocrine therapy1333(96.5)891(66.8)336(24.3)591(45.6)Adjuvant endocrine therapy47(3.4)441(33.1)1036(75.0)679(52.4)Neoadjuvant endocrine therapy1(0.1)1(0.1)9(0.7)24(1.9)Neoadjuvant + adjuvant endocrine therapy0(0.0)0(0.0)1(0.1)2(0.2)**Type of endocrine therapy, n (%)**Aromatase Inhibitor ± tamoxifen0(0.0)0(0.0)5(0.4)76(5.9)Tamoxifen44(3.2)397(29.8)1032(74.7)629(48.5)Ovarian ablation3(0.2)42(3.2)5(0.4)0(0.0)Other endocrine therapy1(0.1)3(0.2)4(0.3)0(0.0)No endocrine therapy1333(96.5)891(66.8)336(24.3)591(45.6)**(Neo)adjuvant chemotherapy, n (%)**No chemotherapy1182(85.6)1180(88.5)967(70.0)794(61.3)Adjuvant chemotherapy199(14.4)148(11.1)358(25.9)449(34.6)Neoadjuvant chemotherapy0(0.0)5(0.4)47(3.4)43(3.3)Neoadjuvant + adjuvant chemotherapy0(0.0)0(0.0)10(0.7)10(0.8)**Type of chemotherapy, n (%)**Taxanes ± Anthracyclines0(0.0)0(0.0)4[b](#tbl2fnb){ref-type="table-fn"}(0.3)33(2.5)Anthracyclines72(5.2)153(11.5)399(28.9)468(36.1)Other chemotherapy127(9.2)0(0.0)12(0.9)1(0.1)No chemotherapy1182(85.6)1180(88.5)967(70.0)794(61.3)[^4][^5]

3.2. Overall survival from diagnosis {#sec3.2}
------------------------------------

The risk of dying from breast cancer progressively decreased for each consecutive time period; the unadjusted data showed a decrease in risk of dying of on average 37% over the four decades. HRs relative to those women in the earliest time period (1975--1982) diminished over time. Overall survival was positively associated with receiving (neo)adjuvant radio-, (neo)adjuvant chemo- and adjuvant endocrine therapy, with changes in HR from 0.72 in P3 and 0.64 in P4 to 0.77 and 0.69 respectively when adjusted for these treatment modalities ([Table 3](#tbl3){ref-type="table"}).Table 3Risk of mortality from date of surgery for each cohort and adjusted for various potential covariates.Table 3Model1975--19821983--19901991--19981999--200611.00Ref.0.89(0.80--0.99)0.69(0.62--0.78)0.63(0.56--0.71)21.00Ref.0.88(0.79--0.98)0.72(0.64--0.80)0.63(0.56--0.70)31.00Ref.0.89(0.80--1.00)0.72(0.65--0.81)0.64(0.57--0.72)41.00Ref.0.93(0.83--1.04)0.77(0.67--0.90)0.69(0.60--0.81)[^6][^7][^8][^9]

3.3. Risk of metastasis {#sec3.3}
-----------------------

Using the Kaplan-Meier estimator, the probability of developing metastasis at 8 years after diagnosis successively diminished over each time period from 42% in P1, to 35% in P2, 22% in P3, and 9% in P4. This constitutes a HR of 0.23 (95%-CI 0.19--0.27) for development of metastasis for P4 compared to P1 ([Table 4](#tbl4){ref-type="table"}). The percentage of tumours \<2 cm increased from 29.1% to 47.4%, with the percentage of women receiving (neo)adjuvant radio-, (neo)adjuvant chemo- and adjuvant endocrine therapy equally increasing ([Table 2](#tbl2){ref-type="table"}). Yet, the covariates of tumour size, nodal status, histological grade, histological type, ER-status, PgR-status, (neo)adjuvant chemo-, (neo)adjuvant radio-, and adjuvant endocrine therapy did not individually substantially influence the HR for developing distant metastases ([Table 4](#tbl4){ref-type="table"}). The proportion of women with a local recurrence who subsequently developed metastasis decreased from 53.1% in P1 through to 25.4% in P4 ([Table 5](#tbl5){ref-type="table"}).Table 4Risk of distant metastases from year of surgery for each cohort and adjusted for various potential covariates.Table 4Model1975--1982 (number of events: 612)1983--1990 (number of events: 504)1991--1998 (number of events: 348)1999--2006 (number of events: 158)11.00Ref.0.79(0.70--0.89)0.48(0.42--0.55)0.23(0.19--0.27)21.00Ref.0.81(0.72--0.91)0.51(0.45--0.59)0.24(0.20--0.28)31.00Ref.0.82(0.72--0.92)0.52(0.45--0.59)0.24(0.20--0.29)41.00Ref.0.81(0.71--0.93)0.53(0.44--0.63)0.23(0.19--0.29)[^10][^11][^12][^13]Table 5Demographic features, histopathological characteristics and treatment modalities of women diagnosed with secondary metastases per time period. ER = oestrogen receptor, PgR = progesterone receptor, HER2 = human epithelial growth factor receptor 2.Table 51975--1982 (n = 575)1983--1990 (n = 467)1991--1998 (n = 304)1999--2006 (n = 118)Age at surgery, n (%)\<4050(8.7)57(12.2)43(14.1)15(12.7)40--49146(25.4)90(19.3)76(25.0)21(17.8)50--59196(34.1)148(31.7)82(27.0)28(23.7)60--69117(20.3)109(23.3)66(21.7)30(25.4)70+66(11.5)63(13.5)37(12.2)24(20.3)**Time to metastases, n (%)**0--1 years107(18.6)77(16.5)34(11.2)25(21.2)1--2 years128(22.3)104(22.3)69(22.7)28(23.7)2--5 years190(33.0)155(33.2)112(36.8)45(38.1)5 + years150(26.1)131(28.1)89(29.3)20(16.9)**Site of metastasis, n (%)**Bone65(11.3)71(15.2)49(16.1)14(11.9)Visceral510(88.7)396(84.8)255(83.9)104(88.1)**Local recurrence, n (%)**No Local Rec270(47.0)210(45.0)198(65.1)88(74.6)Local Rec \< 2154(26.8)129(27.6)37(12.2)15(12.7)Local Rec≥2151(26.3)128(27.4)69(22.7)15(12.7)**Nodal status, n (%)**Negative155(27.0)126(27.0)67(22.0)18(15.3)Positive352(61.2)296(63.4)210(69.1)87(73.7)Missing68(11.8)45(9.6)27(8.9)13(11.0)**No of lymph nodes involved, n (%)**0155(27.0)126(27.0)67(22.0)18(15.3)1--3167(29.0)148(31.7)100(32.9)40(33.9)4+185(32.2)148(31.7)110(36.2)47(39.8)Missing68(11.8)45(9.6)27(8.9)13(11.0)**Tumour size, n (%)**\<2 cm111(19.3)109(23.3)105(34.5)29(24.6)2--5 cm419(72.9)323(69.2)172(56.6)73(61.9)5 + cm30(5.2)29(6.2)22(7.2)13(11.0)Missing15(2.6)6(1.3)5(1.6)3(2.5)**Histological type, n (%)**Ductal469(81.6)382(81.8)243(79.9)93(78.8)Lobular52(9.0)61(13.1)33(10.9)11(9.3)Other/missing54(9.4)24(5.1)28(9.2)14(11.9)**Grade, n (%)**Grade 125(4.3)19(4.1)12(3.9)6(5.1)Grade 2260(45.2)203(43.5)84(27.6)28(23.7)Grade 3195(33.9)181(38.8)168(55.3)69(58.5)Unknown/missing95(16.5)64(13.7)40(13.2)15(12.7)**ER-status, n (%)**Negative188(32.7)144(30.8)92(30.3)41(34.7)Positive321(55.8)302(64.7)186(61.2)71(60.2)Missing data66(11.5)21(4.5)26(8.6)6(5.1)**PgR-status, n (%)**Negative266(46.3)239(51.2)140(46.1)60(50.8)Positive210(36.5)206(44.1)138(45.4)52(44.1)Missing data99(17.2)22(4.7)26(8.6)6(5.1)**HER2-status, n (%)**Negative191(33.2)216(46.3)154(50.7)58(49.2)Positive58(10.1)79(16.9)65(21.4)38(32.2)Missing data326(56.7)172(36.8)85(28.0)22(18.6)**High risk subpopulation**[a](#tbl5fna){ref-type="table-fn"}St Gallen 'High Risk' + Grade 398(17.0)101(21.6)91(29.9)52(44.1)Other/missing477(83.0)366(78.4)213(70.1)66(55.9)**Surgery, n (%)**Mastectomy485(84.3)265(56.7)159(52.3)68(57.6)Breast conservation90(15.7)202(43.3)145(47.7)50(42.4)**Radiation therapy**[b](#tbl5fnb){ref-type="table-fn"}**, n (%)**Yes286(49.7)275(58.9)205(67.4)95(80.5)No289(50.3)192(41.1)99(32.6)23(19.5)**Endocrine therapy**[b](#tbl5fnb){ref-type="table-fn"}**, n (%)**Yes255(44.3)274(58.7)258(84.9)72(61.0)No320(55.7)193(41.3)46(15.1)46(39.0)**Chemotherapy**[b](#tbl5fnb){ref-type="table-fn"}**, n (%)**Yes136(23.7)143(30.6)183(60.2)81(68.6)No439(76.3)324(69.4)121(39.8)37(31.4)[^14][^15]

3.4. Onset of metastasis {#sec3.4}
------------------------

[Table 5](#tbl5){ref-type="table"} shows patient demographics, histopathological characteristics, and treatment modalities for those women who developed secondary metastasis. The proportion of women developing metastasis ≤5 years after primary surgery decreased slightly from P1 to P3 (73.9%, 72.0%, and 70.7% respectively), but increased again to 83.0% in P4. The most marked difference was for the group of women developing metastasis ≤1 year; this proportion of women initially decreased from 18.6% to 16.5% and 11.2% for P1 to P3 respectively, but then nearly doubled to 21.2% in P4.

3.5. Overall survival from onset of metastasis {#sec3.5}
----------------------------------------------

In women who developed metastasis, the median survival after diagnosis of metastasis decreased from 1.49 years (95%-CI 1.32--1.69) in P1 to 1.25 years (95%-CI 1.06--1.47), 0.85 years (95%-CI 0.65--1.01) and 0.94 years (95%-CI 0.61--1.32) in P2, P3, and P4 respectively -- a decrease of 6.6 months in survival from onset of metastasis over the 40-year period ([Fig. 1](#fig1){ref-type="fig"}A).Fig. 1Kaplan-Meier estimators of mortality probability from metastatic disease over time, with t = 0 the time of onset of metastasis: A. shows the whole patient cohort included in this study and B. only the high-risk subpopulation. Whereas A. seems to indicate a decrease in survival for more recent time periods; B. shows that the high-risk subpopulations, have similar mortality rates post-metastasis which are seen across all time periods. Within the graph, the median survival in years after metastasis onset and the 95% CI for each time period is presented. Below the graph are the figures for the absolute number of patients at risk.Fig. 1

In unadjusted analysis, women in P4 had a 43% higher chance of dying from metastasis compared to P1, during a median follow-up of 1.2 years ([Table 6](#tbl6){ref-type="table"}). From adjusted model 5 (see [Table 6](#tbl6){ref-type="table"}) onwards, where the HRs were adjusted for (neo)adjuvant radio-, (neo)adjuvant chemo-, and adjuvant endocrine therapy rather than only histopathological features, the HR in P4 versus P1 diminished from 1.28 to 1.02. Additional adjustments for the treatment of local recurrence and distant metastases, resulted in a consistent HR for P4 versus P1.Table 6Hazard ratios of mortality after the onset of metastasis for each cohort, with a median follow-up of 1.2 years (Q1 = 0.44 years, Q3 = 2.4 years).Table 6Model1975--1982 (number of deaths: 517)1983--1990 (number of deaths: 428)1991--1998 (number of deaths: 292)1999--2006 (number of deaths: 113)11.00Ref.1.11(0.98--1.26)1.57(1.36--1.82)1.43(1.18--1.74)21.00Ref.1.17(1.03--1.34)1.78(1.54--2.06)1.41(1.15--1.71)31.00Ref.1.15(1.01--1.30)1.56(1.34--1.82)1.27(1.03--1.55)41.00Ref.1.18(1.03--1.34)1.63(1.39--1.90)1.28(1.05--1.58)51.00Ref.1.10(0.95--1.26)1.23(1.00--1.51)1.02(0.80--1.31)61.00Ref.1.09(0.95--1.25)1.23(1.00--1.52)1.01(0.79--1.29)71.00Ref.1.06(0.93--1.22)1.13(0.92--1.40)0.94(0.73--1.21)[^16][^17][^18][^19][^20][^21][^22]

3.6. High risk subpopulation {#sec3.6}
----------------------------

Applying selection criteria based on the St. Gallen criteria and the grade of the primary tumour, subsets of women with similar prognostic features were extracted from the cohort.^15^ Within all four time periods a subset of a similar number of women -- P1: 177, P2: 183, P3: 222 and P4: 196 -- with the high-risk St. Gallen Criteria and tumour grade 3 was identified ([Fig. 2](#fig2){ref-type="fig"}). From this high-risk subset, the overall survival of those women developing metastasis was plotted ([Fig. 1](#fig1){ref-type="fig"}B), showing that the mortality probability was similar for these women across the four time periods.Fig. 2Schematic representation of a high-risk subpopulation of women who develop metastasis early and subsequently quickly succumb to their metastatic disease present in every cohort. The presence of these women with poor prognosis is obscured in earlier cohorts due to the number of women developing metastasis then.Fig. 2

4. Discussion {#sec4}
=============

As previously described \[[@bib1],[@bib14],[@bib15]\] the overall survival from breast cancer improved over four decades by approximately 40% and the risk of developing metastasis decreased by 80%. The decrease of HR for overall mortality between 1983-1990 and 1991--1998 in this study is likely to be due to a combination of the introduction of the NHSBSP in 1988 and better treatment modalities \[[@bib5],[@bib16]\]. However, when adjusting for tumour size and nodal status, i.e. surrogate markers of earlier detection, only a negligible change in the HRs was seen in P3 and P4 compared with P1 suggesting that lead-time bias is not a significant factor in the increased survival noted. Conversely, the increase in mortality HR from 0.63 (crude analysis) to the adjusted HR of 0.69 in the last time period (P4) suggests that (neo)adjuvant radiotherapy, (neo)adjuvant chemotherapy and adjuvant endocrine therapy are more important contributors to the improvement in overall survival ([Table 3](#tbl3){ref-type="table"}).

The number of women with primary operable breast cancer who subsequently developed metastasis decreased during each time period analysed. This could also have been anticipated with advances in screening and treatment \[[@bib17], [@bib18], [@bib19], [@bib20]\]. However, these data show that none of the tumour characteristics, (neo) adjuvant radiotherapy, (neo)adjuvant chemotherapy or adjuvant endocrine therapy fully account for this decreasing risk of metastasis over the studied time period. Within each time group, when compared to the first cohort, the HRs are consistent over all of the adjustment models, for example, approximately 78% reduction in risk for all adjustment models in P4 compared to P1. To understand this pattern, individual data on screening exposure and correction for lead-time would be necessary. There is a theoretical possibility that treatment interacts with early, pre-symptomatic detection to make the treatment more effective, which partly would explain the findings. Furthermore, to tease out the problem, individual data on detection mode of distant metastases would be needed; improved diagnostics and changed criteria over time means that both women with and without metastases in the four cohorts differ. However, concerning the latter, it is probable that our estimates of a drift towards shorter survival after distant metastases are conservative. Local recurrence, following breast-conserving surgery and post-operative radiotherapy, is a well-recognised independent risk factor for distant metastasis \[[@bib21]\]. The reduction in local recurrence observed over the time period is also likely to have contributed to the decrease in metastasis \[[@bib22]\].

Despite the overall decline in the risk of development of secondary metastasis over the time periods, in those women who developed metastasis, the proportion who did so within 1 year of diagnosis was highest in the most recent time period (22.1%). The median survival from the time of diagnosis of metastatic disease also diminished from 1.49 years to 0.94 years over the 4 decades, with an increase in mortality risk of 40%.

It is recognised that women with a shorter distant metastasis free interval (DMFI) have a shorter survival time following development of the metastasis \[[@bib23],[@bib24]\] and that receptor status, e.g. HER2 positive and triple negative disease, correlates with a higher risk of (early) metastatic disease \[[@bib25],[@bib26]\]. In this series, tumours in women who subsequently developed metastatic disease showed consistent ER- and PgR-expression over the four time periods, whereas the proportion of HER2 positive disease increased over the years. Assessment of HER2 expression was standard from halfway through P2 onwards, thereby explaining the apparent increase in HER2 positive cases in later cohorts \[[@bib12]\].

The mean survival time following diagnosis with metastasis decreased from 17.9 months in the first time period, to 15 months, 10.2 months and 11.3 months in P2, P3, and P4, respectively. This is in contrast to several other studies where an increase in survival over time after diagnosis of distant disease has been reported \[[@bib27], [@bib28], [@bib29], [@bib30]\]. Of these studies Andre et al. report on synchronous metastases \[[@bib27]\] and Ernst et al. primary metastatic breast cancer \[[@bib29]\] rather than secondary metastatic disease. The women in these studies will therefore not have received adjuvant chemotherapy prior to their metastatic treatment. Giordano et al. combined local relapse and distant metastases in their evaluation, impeding interpretation in the context of this study \[[@bib28]\]. Lastly, Chia et al. describe a decreased post-metastatic use of anthracyclines and an increase of taxanes with an improved survival from metastatic breast cancer between 1991 and 2001 \[[@bib30]\]. Other studies, however, have described similar findings to those reported here with shorter overall survival from metastatic breast cancer \[[@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38]\]. A large German multi-centre study evaluating 60,227 breast cancer patients found an increasing cure rate as a result of improved systemic treatment and a similar reduction in post-metastatic survival over a comparable time period (1978--2013) \[[@bib34]\]. Recently, a comprehensive overview of post-metastatic shortening of survival and the role of adjuvant treatment was given by Fink \[[@bib33]\].

This poorer post-metastatic overall could possibly be explained by adjuvant systemic treatment, as inherently adjuvant systemic treatment is given to higher risk tumours. Less malignant tumour cells are eliminated leaving only the most aggressive clones of tumour cells. Adjuvant systemic treatment-induced resistance may occur in those remaining clones of tumour cells, as they have had prior exposure to the adjuvant systemic treatment. Re-exposure to chemotherapy is less effective. This effect is seen in women treated with doxorubicin and taxanes or Cyclophosphamide Methotrexate Fluorouracil (CMF) - the so-called ATRESS phenomenon (adjuvant therapy-related shortening of survival). The administration of these drugs to treat primary breast cancer has been suggested to decrease overall survival from the time of diagnosis of metastatic disease by one-third \[[@bib31], [@bib32], [@bib33],[@bib35], [@bib36], [@bib37],[@bib39]\]. We have found a similar one-third reduction in post-metastatic survival when comparing P1 to P4 \[[@bib35],[@bib37]\]. Of note, in the first cohort, taxanes and anthracyclines were not clinically available for adjuvant treatment of primary breast cancer \[[@bib40],[@bib41]\]. It is probable that the addition of adjuvant taxanes could further diminish post-metastatic survival \[[@bib36]\]. Moreover, the HR for metastatic survival diminishing to approximately 1.00 in P4 when adjusted for treatment to the primary tumour makes it probable that effectively the difference in survival from time of metastasis between the women within the four different time periods is related to their response to differences in treatment regimens to the primary tumour (adjustment model 5 in [Table 6](#tbl6){ref-type="table"}). This phenomenon has also been demonstrated in other solid tumours, e.g. colorectal cancer \[[@bib42]\]. It is probable that applying a selective pressure such as chemotherapy could cause the emergence of treatment-resistant clones \[[@bib43]\]. As the use of chemotherapy is disputed for lobular breast cancer \[[@bib44]\], sub-analyses of women with lobular breast cancer was performed. The data showed wide confidence intervals, indicating limit power and therefore no meaningful conclusions could be drawn.

4.1. Strengths and weaknesses {#sec4.1}
-----------------------------

Other studies \[[@bib17],[@bib20],[@bib34],[@bib37],[@bib45],[@bib46]\] have described changes in the clinical pattern of breast cancer and metastatic breast cancer over a short-to-medium term, though none have reported such a large cohort of breast cancer patients, including systemic treatment details, from a single centre over an extensive period of 40 years.

The data in this study has been prospectively recorded since the establishment of the breast cancer database at Guy's Hospital, providing complete and reliable clinical data. The data has been collected in one centre, which may limit the generalisability of the results but, conversely, ensures a relatively consistent patient population over time.

Significant changes have taken place in the past four decades in both diagnostic and treatment modalities and management protocols for breast cancer. By adjusting for predetermined confounding factors these variations in diagnosis and treatment have been partly mitigated.

5. Conclusions {#sec5}
==============

Although the risk of developing metastasis has decreased and overall survival from breast cancer has improved over the last four decades, there remains a group of women who develop metastasis early and in whom prognosis remains poor. This could potentially be a result of adjuvant systemic treatment-induced resistance seen in those treated with doxorubicin, taxanes or Cyclophosphamide Methotrexate Fluorouracil - the so-called ATRESS phenomenon which merits further investigation. The next step will be to identify a molecular signature in treatment resistant women, intersecting with the high-risk subgroup of women, to define better targeted treatment options.
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The following is the Supplementary data to this article:Multimedia component 1Multimedia component 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.breast.2020.01.006>.

[^1]: Histologic and/or nuclear grade.

[^2]: pT, pathological tumour size (i.e. size of the invasive component).

[^3]: ER, oestrogen receptor; PgR, progesterone receptor. Table derived from Goldhirsch et al., 2007 \[[@bib13]\].

[^4]: Based on the mean of 5 imputation datasets.

[^5]: 1 Woman received taxanes alone.

[^6]: **Model 1**: Crude analysis.

[^7]: **Model 2**: Adjusted Tumour size (\<2 cm/2--5 cm/5 + cm), Nodal status (Negative/Positive), and age.

[^8]: **Model 3**: As Model 2 with further adjustment for Tumour grade (Grade 1/Grade 2/Grade 3), Histological type (Ductal/Lobular/Tubular/Other), ER-status (Negative/Positive), and PgR-status (Negative/Positive), and Her2-status (Negative/Positive).

[^9]: **Model 4**: As Model 3 with further adjustment for (neo)adjuvant Chemotherapy (Yes/No), (neo)adjuvant Radiotherapy (Yes/No), and adjuvant Endocrine treatment (Yes/No) regarding primary tumour.

[^10]: **Model 1**: Crude analysis.

[^11]: **Model 2**: Adjusted Tumour size (\<2 cm/2--5 cm/5 + cm), Tumour grade (Grade 1/Grade 2/Grade 3), and age.

[^12]: **Model 3**: As Model 2 with further adjustment for Nodal status (Negative/Positive), Histological type (Ductal/Lobular/Tubular/Other), ER-status (Negative/Positive), and PgR-status (Negative/Positive), and Her2-status (Negative/Positive).

[^13]: **Model 4**: As Model 3 with further adjustment for (neo)adjuvant Chemotherapy (Yes/No), neo(adjuvant) Radiotherapy (Yes/No), and adjuvant Endocrine treatment (Yes/No) regarding primary tumour.

[^14]: Based on the mean of 5 imputation datasets.

[^15]: Including treatment to the primary tumour and treatment for local recurrence.

[^16]: **Model 1**: Crude analysis.

[^17]: **Model 2**: Adjusted for Time to metastases (0--1 years/1--2 years/2--5 years/5 + years), Site of metastases (Bone/Visceral), and local recurrence (No Local Rec/Local recurrence within 2 years/Local recurrence later than 2 years).

[^18]: **Model 3**: As Model2 with further adjustment for Tumour size (\<2 cm/2--5 cm/5 + cm), Nodal status (Negative/Positive), and Tumour grade (Grade 1/Grade 2/Grade 3).

[^19]: **Model 4**: As Model3 with further adjustment for Histological type (Ductal/Lobular/Other), ER-status (Negative/Positive), and PgR-status (Negative/Positive).

[^20]: **Model 5**: As Model4 with further adjustment for (neo)adjuvant Chemotherapy (Yes/No), (neo)adjuvant Radiotherapy (Yes/No), and adjuvant Endocrine treatment (Yes/No) regarding primary tumour.

[^21]: **Model 6**: As Model5 with further adjustment for adjuvant Chemotherapy (Yes/No), adjuvant Radiotherapy (Yes/No), and adjuvant Endocrine treatment (Yes/No) regarding local recurrence.

[^22]: **Model 7**: As Model6 with further adjustment for post-metastatic Chemotherapy (Yes/No), post-metastatic Radiotherapy (Yes/No), post-metastatic Endocrine treatment (Yes/No), and anti-body treatment (Yes/No) regarding distant metastases.
